Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 5 de 5
Filtrar
Mais filtros










Filtros aplicados
Base de dados
Intervalo de ano de publicação
1.
Adv Rheumatol ; 60: 02, 2020. tab
Artigo em Inglês | LILACS | ID: biblio-1088645

RESUMO

Abstract Background: The aims of this article were to assess the prevalence of nephrolithiasis and the factors associated with nephrolithiasis in Brazilian patients with primary gout. Methods: One hundred twenty-three patients with primary gout were recruited from a tertiary referral hospital in São Paulo, Brazil. All patients underwent ultrasonography and had their clinical and laboratory characteristics assessed. Results: One hundred fifteen (93.5%) patients were male, with a mean age of 62.9 ± 9.4 years. Twenty-three (18.7%) patients had asymptomatic nephrolithiasis (detected only by ultrasonography), 7 (6.0%) had symptomatic nephrolithiasis (detected by ultrasonography and a positive clinical history), and 13 (10.0%) had a history of kidney stones, but ultrasonography at evaluation did not show nephrolithiasis. Therefore, 35.0% of the patients had nephrolithiasis (detected either by ultrasonography and/or a positive clinical history). Nephrolithiasis was associated with male gender (43 [100%] vs 72 [90%], p = 0.049), the use of potassium citrate (13 [30.2%] vs 0, p < 0.001) and the use of medications for diabetes (10 [23.3%] vs 8 [10%], p = 0.047) and dyslipidemia (15 [34.9%] vs 10 [12.5%], p = 0.003); benzbromarone had an inverse association with nephrolithiasis (21 [48.8%] vs 55 [68.8%], p = 0.030). In patients with and without nephrolithiasis, no differences were found in the laboratory and ultrasonography characteristics, including serum uric acid levels, urinary uric acid excretion and urine pH. Conclusions: The prevalence of nephrolithiasis in primary gout was 35.0%, and 18.7% of the patients were asymptomatic. Nephrolithiasis was associated with male gender, diabetes and dyslipidemia. A positive history of nephrolithiasis probably biased the prescription of potassium citrate and benzbromarone.(AU)


Assuntos
Humanos , Síndrome Metabólica , Nefrolitíase/epidemiologia , Gota/fisiopatologia , Brasil/epidemiologia , Benzobromarona/efeitos adversos , Prevalência , Citrato de Potássio/efeitos adversos , Urolitíase/etiologia
2.
Adv Rheumatol ; 59: 37, 2019.
Artigo em Inglês | LILACS | ID: biblio-1088617

RESUMO

Abstract Background Benzbromarone is a uricosuric drug that has been used in the treatment of gout over the last 30 years. Due to its potent inhibition of the dominant apical (luminal) urate exchanger in the human proximal tubule URAT1, it reduces the urate reabsorption, diminishing serum urate levels and therefore preventing gout flares. Main body of the abstract Through several clinical trials, Benzbromarone has been proved effective and safe, inclusive in patients with chronic kidney disease and as combination therapy with allopurinol. Due to hepatotoxicity reports, it was withdrawn from the European market by the manufacturer, however many authors have questioned the product's withdrawal due to a lack of clinical evidence in order to support its hepatotoxicity. Benzbromarone is still available in several European countries, New Zealand, Brazil and several other countries. Despite the product's marketing over more than 20 years after the first hepatotoxicity reports, we have found only five reports in our literature search, and no prospective or retrospective study correlating hepatotoxicity with benzbromarone use. Short conclusion Benzbromarone is a safe and effective molecule for the treatment of gout. However, due to in vitro and in vivo data related to hepatotoxicity, it is prudent to prescribe it with some caution, especially for patients with an already known liver condition.


Assuntos
Humanos , Benzobromarona/uso terapêutico , Gota/tratamento farmacológico , Alopurinol/administração & dosagem , Combinação de Medicamentos , Efeitos Colaterais e Reações Adversas Relacionados a Medicamentos
3.
Folha méd ; 90(1/2): 55-8, jan.-fev. 1985. tab
Artigo em Português | LILACS | ID: lil-30217

RESUMO

A funçäo renal de 20 pacientes portadores de gota primária foi avaliada em estudo aberto, näo comparativo e unicêntrico, na vigência de tratamento com benzobromarona*. Foram incluídos no presente estudo somente pacientes normo ou hipoexcretores de ácido úrico. O fármaco foi administrado por via oral, na posologia de 100 mg diários, em uma única tomada, durante três semanas. Constatou-se um flagrante aumento da uricosúria em todos os casos avaliados, bem como uma acentuada reduçäo da uricemia. Os valores de calcemia, calciúria, fosfatemia, uréia, creatinina, sódio, potássio e a clearance de creatinina urinária näo mostraram alteraçöes importantes. Quanto à tolerabilidade ao medicamento, esta foi considerada boa, apesar de efeitos colaterais, facilmente controláveis, estarem presentes em 10 (50%) pacientes. Em nenhum dos casos foi necessário interromper-se a terapia


Assuntos
Humanos , Masculino , Feminino , Benzobromarona/uso terapêutico , Gota/tratamento farmacológico , Benzobromarona/efeitos adversos , Testes de Função Renal
SELEÇÃO DE REFERÊNCIAS
DETALHE DA PESQUISA
...